COVID-19 Outbreak Information –

Raymond De Vré

Chief Executive Officer of PolyPeptide Group

Raymond De Vré, Chief Executive Officer of PolyPeptide Group, is a Belgian citizen born in 1968. Mr. De Vré joined PolyPeptide Group on 1 April 2021 and became CEO on the day of its listing on 29 April 2021. He joined the company from Dr. Reddy’s Laboratories (DRL), a multinational pharmaceutical company, where he served as Senior Vice President, Head Biologics and as a member of the Management Committee from 2018 to 2021. Prior to that, at DRL he was Senior Vice President Global Business Operations and Strategy, Biologics from 2017 to 2018 and Vice President Commercial, Biologics between 2012 and 2017. Before starting his tenure at DRL, Mr. De Vré was a Partner of McKinsey & Company from 2004 until 2011 as well as a consultant from 1996 until 2003. In his roles at McKinsey, he advised companies in the areas of generics, pharmaceutical, biotech, and specialty chemicals across multiple geographies, especially Europe, the U.S., and India. Mr. De Vré holds a PhD in Applied Physics from Stanford University, California and a Master’s degree in Engineering from Université Libre de Bruxelles.